Latest Commercial Agreements News

GCM Corporation finalises exclusive rights to its Very High Density technology, launches its first commercial heat sink products, and expands global prototyping efforts targeting high-growth sectors including EV infrastructure and data centres.

LTR Pharma has wrapped up recruitment for its SPONTAN Phase II pharmacokinetic study, with interim results expected soon to bolster FDA approval efforts. Meanwhile, US commercial talks for ROXUS advance cautiously under the FDA 503(a) personalised medicine pathway.

NH3 Clean Energy has marked strong progress in its WAH2 clean ammonia project by appointing Linde Engineering for FEED and securing a 15-year water supply agreement, setting the stage for a final investment decision by year-end.

Firebird Metals has locked in exclusive global rights to key LMFP patents through 2045 and commissioned lithium-manganese-rich cathode equipment, progressing its Australian Demonstration Plant with a $2 million ARENA grant.

Structural Monitoring Systems Plc reported a 55% jump in quarterly free cash flow to $1.4 million and eliminated its bank debt by repaying a C$0.8 million term loan. The company also launched the MTP138 radio targeting offshore markets and secured key certifications for its avionics products.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Botanix Pharmaceuticals has agreed to terms with Piramal to establish an alternate supplier for the active ingredient in Sofdra, aiming to reduce costs by up to 40% and strengthen its supply chain.

International Graphite Limited (ASX: IG6) and ALKEEMIA have achieved graphite purification exceeding 99.9% total graphitic carbon across diverse concentrate samples, reinforcing their joint venture plans to build a major processing hub in Italy.

IODM Limited has renewed its commercial agreement with Convera for the UK higher education sector, increasing its revenue share and shifting to a non-exclusive arrangement that broadens its market opportunities.

Vitrafy Life Sciences has announced the completion of Phase II testing of a platelet cryopreservation study with the U.S. Army Institute of Surgical Research, showing consistent results for the legacy wash-based protocol and encouraging outcomes for an innovative no-wash approach.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

NH3 Clean Energy has entered a pivotal phase in its WAH2 Project development, partnering with global engineering giant Linde and progressing funding discussions to secure up to A$567 million. This collaboration aims to reduce capital and operational risks as the project moves closer to a final investment decision.